This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameInfigratinib
Accession NumberDB11886
TypeSmall Molecule
GroupsInvestigational
Description

Infigratinib is under investigation for the treatment of Head and Neck Squamous Cell Carcinoma.

Structure
Thumb
SynonymsNot Available
External IDs BGJ-398 / BGJ398
Product Ingredients
IngredientUNIICASInChI KeyDetails
Infigratinib Acetate03D0789NYP 1310746-17-8XHCQHOGMMJKLRU-UHFFFAOYSA-NDetails
Infigratinib HydrochlorideWY8VD4RV77 1310746-15-6VBAIJSJSFCXDJB-UHFFFAOYSA-NDetails
Infigratinib MesylateE223Z0KWCC 1310746-12-3BXJJFNXYWJLBOS-UHFFFAOYSA-NDetails
Infigratinib Phosphate58BH47BV6S 1310746-10-1GUQNHCGYHLSITB-UHFFFAOYSA-NDetails
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIA4055ME1VK
CAS number872511-34-7
WeightAverage: 560.475
Monoisotopic: 559.186543307
Chemical FormulaC26H31Cl2N7O3
InChI KeyQADPYRIHXKWUSV-UHFFFAOYSA-N
InChI
InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)
IUPAC Name
N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-N-methylcarbamimidic acid
SMILES
CCN1CCN(CC1)C1=CC=C(NC2=CC(=NC=N2)N(C)C(O)=NC2=C(Cl)C(OC)=CC(OC)=C2Cl)C=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Bgj398.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Bgj398.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bgj398.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Bgj398.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Bgj398.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Bgj398.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Bgj398.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bgj398.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Bgj398.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Bgj398.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bgj398.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Bgj398.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdvanced Solid Tumors With Alterations of FGFR1, 2 and or 3 / Advanced Solid Tumors With Alterations of FGFR1, 2 and/or 3 / Advanced Solid Tumors With FGFR1 Amplication / Advanced Solid Tumors With FGFR2 Amplication / Advanced Solid Tumors With FGFR3 Mutation / Bladder Cancer With FGFR3 Mutation or Fusion / Squamous Lung Cancer With FGFR1 Amplification1
1CompletedTreatmentAdvanced Solid Tumors / Metastatic Solid Tumors1
1RecruitingTreatmentTumor With Alterations of the FGF-R1
1WithdrawnTreatmentCancer of Cervix / Tumors1
1, 2Active Not RecruitingTreatmentAdvanced Gastrointestinal Stromal Tumor (GIST)1
1, 2WithdrawnTreatmentAdenocarcinoma of the Pancreas / Colon Adenocarcinoma / Pancreatic Adenocarcinoma Metastatic / Pancreatic Ductal Adenocarcinoma / Rectal Adenocarcinoma / Stage III Pancreatic Cancer / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2Active Not RecruitingTreatmentMelanoma1
2Active Not RecruitingTreatmentRecurrent Glioblastoma or Other Glioma Subtypes1
2Not Yet RecruitingTreatmentFGFR Gene Amplification / FGFR1 Gene Amplification / FGFR2 Gene Amplification / FGFR2 Gene Mutation / FGFR3 Gene Mutation / Head and Neck Squamous Cell Carcinoma (HNSCC) / Human Papillomavirus Infections / Recurrent Head and Neck Carcinoma / Recurrent Nasopharynx Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma1
2RecruitingTreatmentAdvanced Cholangiocarcinoma1
2RecruitingTreatmentMalignancies, Hematologic / Tumors, Solid1
Not AvailableRecruitingTreatmentBladder Cancers / Non-Muscle-Invasive Urothelial Carcinoma1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0183 mg/mLALOGPS
logP4.9ALOGPS
logP4.56ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)7.2ChemAxon
pKa (Strongest Basic)8.28ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area98.58 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity154.58 m3·mol-1ChemAxon
Polarizability58.63 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative ParentsN-arylpiperazines / Dimethoxybenzenes / N-phenylureas / Methoxyanilines / Dialkylarylamines / Dichlorobenzenes / Phenoxy compounds / Anisoles / Alkyl aryl ethers / N-alkylpiperazines
SubstituentsN-arylpiperazine / Phenylpiperazine / Dimethoxybenzene / M-dimethoxybenzene / N-phenylurea / Methoxyaniline / 1,3-dichlorobenzene / Phenol ether / Methoxybenzene / Tertiary aliphatic/aromatic amine
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsN-arylpiperazine, ureas, aminopyrimidine, dichlorobenzene, N-alkylpiperazine (CHEBI:63451 )
Drug created on October 20, 2016 14:57 / Updated on September 01, 2017 12:14